277 related articles for article (PubMed ID: 33551091)
1. [Therapeutic drug monitoring of antidepressants: Why venlafaxine is the most monitored drug? A review of literature].
Couderc S; Mory C; Darnaud L; Saint-Marcoux F
Therapie; 2021; 76(6):725-733. PubMed ID: 33551091
[TBL] [Abstract][Full Text] [Related]
2. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
Kringen MK; Bråten LS; Haslemo T; Molden E
J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.
Reis M; Lundmark J; Björk H; Bengtsson F
Ther Drug Monit; 2002 Aug; 24(4):545-53. PubMed ID: 12142641
[TBL] [Abstract][Full Text] [Related]
4. Effect of venlafaxine dosage, valproic acid concentration, sex, and age on steady state dose-corrected concentrations of venlafaxine and O-desmethylvenlafaxine: A retrospective analysis of therapeutic drug monitoring data in a Chinese population.
Wang ZZ; Deng SH; Lu HY; Li L; Zhu XQ; Hu JQ; Xie HS; Chen HZ; Chen YQ; Zhang M; Fang ZY; Wen YG; Shang DW
Hum Psychopharmacol; 2020 May; 35(3):e2733. PubMed ID: 32239743
[TBL] [Abstract][Full Text] [Related]
5. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
6. Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring.
Stamm TJ; Becker D; Sondergeld LM; Wiethoff K; Hiemke C; O'Malley G; Ricken R; Bauer M; Adli M
Pharmacopsychiatry; 2014 Jul; 47(4-5):174-9. PubMed ID: 25054625
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Drug Monitoring of Venlafaxine in an Everyday Clinical Setting: Analysis of Age, Sex and Dose Concentration Relationships.
Hansen MR; Kuhlmann IB; Pottegård A; Damkier P
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):298-302. PubMed ID: 28397349
[TBL] [Abstract][Full Text] [Related]
8. Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis.
Lense XM; Hiemke C; Funk CSM; Havemann-Reinecke U; Hefner G; Menke A; Mössner R; Riemer TG; Scherf-Clavel M; Schoretsanitis G; Gründer G; Hart XM
Psychopharmacology (Berl); 2024 Feb; 241(2):275-289. PubMed ID: 37857898
[TBL] [Abstract][Full Text] [Related]
9. Time course of clinical response to venlafaxine: relevance of plasma level and chirality.
Gex-Fabry M; Balant-Gorgia AE; Balant LP; Rudaz S; Veuthey JL; Bertschy G
Eur J Clin Pharmacol; 2004 Feb; 59(12):883-91. PubMed ID: 14704834
[TBL] [Abstract][Full Text] [Related]
10. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.
Hermann M; Hendset M; Fosaas K; Hjerpset M; Refsum H
Eur J Clin Pharmacol; 2008 May; 64(5):483-7. PubMed ID: 18214456
[TBL] [Abstract][Full Text] [Related]
13. Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI.
Sigurdsson HP; Hefner G; Ben-Omar N; Köstlbacher A; Wenzel-Seifert K; Hiemke C; Haen E
J Neural Transm (Vienna); 2015 May; 122(5):721-9. PubMed ID: 25257248
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP2D6 Genotypes on Venlafaxine Metabolism in Japanese Psychiatric Patients With Depression.
Komahashi-Sasaki H; Yasui-Furukori N; Sasaki T; Shinozaki M; Hayashi Y; Kato K; Inoue Y; Tsuchimine S; Watanabe T; Sugawara N; Shimoda K
Ther Drug Monit; 2021 Oct; 43(5):681-687. PubMed ID: 33306568
[TBL] [Abstract][Full Text] [Related]
15. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.
Grözinger M; Dragicevic A; Hiemke C; Shams M; Müller MJ; Härtter S
Pharmacopsychiatry; 2003 Jan; 36(1):3-6. PubMed ID: 12649767
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects.
Teng R; Kujacic M; Hsia J
Clin Ther; 2014 Sep; 36(9):1217-25. PubMed ID: 25069798
[TBL] [Abstract][Full Text] [Related]
17. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
[TBL] [Abstract][Full Text] [Related]
19. A Massive Venlafaxine Intoxication: Evolution of Cardiac Toxicity with Venlafaxine and O-Desmethylvenlafaxine Elimination Kinetics: A Grand Round.
Couderc S; Gabriel A; Decheiver S; N'Zoué Kanga S; Fikanni A; Flint H; Pihan F; Sahar A; Tifrea M; Tifrea A; Marsaud JP; Vandroux D
Ther Drug Monit; 2024 Apr; 46(2):133-137. PubMed ID: 38158602
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine.
Kowalewski C; Haen E; Hiemke C; Ridders F; Endres K; Gründer G; Paulzen M; Schoretsanitis G
Int Clin Psychopharmacol; 2019 Sep; 34(5):241-246. PubMed ID: 31094902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
